Obesity rates are set to skyrocket, with one in six children and adolescents worldwide forecast to be obese by 2050, according to a new study. But with significant increases predicted within the next five years, the researchers stress urgent action now could turn the tide on the public health crisis.

A new study in the journal Science of the Total Environment found that emissions from onroad vehicles cause 342 premature deaths annually in Greater Boston. Nearly 90 percent of these deaths are linked to elevated levels of nitrogen dioxide in the region. The majority of these health damages were linked to emissions from light-duty trucks, such as SUVs, pickup trucks, vans, and minivans. SUVs have ranked in recent years the most popular car among residents in the Bay State. 

The American Meteorological Society today released a statement which notes that "U.S. leadership in scientific innovation is at risk due to the recent and ongoing reductions in U.S. federal science capabilities. The consequences to the American people will be large and wide-ranging, including increased vulnerability to hazardous weather."

Many roles in the state and local health department workforce are comparatively underpaid, and job requirements are often lower compared to the private sector according to a new study at Columbia University Mailman School of Public Health.

A new USC-led study provides the first nationwide picture of who knows about, carries, and uses naloxone to reverse deadly opioid overdoses. Mireille Jacobson, professor of gerontology at the USC Leonard Davis School of Gerontology and a senior fellow at the USC Schaeffer Center for Health Policy & Economics, said the study was conducted to address the lack of comprehensive data on access to the lifesaving medication and eventually to support work on how it affects the number of deaths attributed to opioid overdoses in the U.S.

Cambridge, MA, Mar 3, 2025 --- Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, and Tenacia Biotechnology (“Tenacia”), a commercial-stage biopharmaceutical company developing and commercializing innovative treatments for nervous system disorders, today announced a strategic research collaboration. Focused on certain potential targets, Insilico and Tenacia will collaborate during the early discovery stage of novel Central Nervous System (CNS) disease therapies, developing small molecule inhibitors from scratch to preclinical candidate nomination.